Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V940 + pembrolizumab + chemotherapy in first-line metastatic squamous NSCLC
2025-520902-37-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing V940 + pembrolizumab + chemotherapy with Placebo to V940 + pembrolizumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Apr 2026; status: authorised.
02
Drugs
intismeran autogene
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2025-520902-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520902-37-00.